Personalized dosimetry as a key for optimizing radioligand therapy (RLT) with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with well-differentiated neuroendocrine tumors - an update on the initial results of the DUONEN multicenter study

Endocrine Abstracts(2024)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要